Eikon Therapeutics Leads 2026 Biotech IPO Surge with Largest Raise Since 2024, Followed by Generate Biomedicines and AgomAb

on

Eikon Therapeutics raised $381 million in its IPO on February 5, 2026, the largest biotech IPO since 2024, topping Aktis Oncology's $318 million; funds support cancer drugs like EIK1001 for melanoma and NSCLC16

Generate Biomedicines, backed by Flagship Pioneering, filed for a Nasdaq IPO (symbol GENB) on February 4, 2026, to advance anti-TSLP antibody GB-0985 in asthma and COPD trials, plus cancer programs GB-4362 and GB-526717

AgomAb Therapeutics priced its Nasdaq IPO (symbol AGMB) at $16 per share, raising about $200-212.5 million; proceeds fund Phase 2b trial of ontunisertib for fibrostenosing Crohn’s disease and Phase 2 of AGMB-447 for IPF125

These IPOs are part of a hot streak with four biotechs (including Spyglass and Veradermics) raising nearly $1 billion in one week, signaling a biotech IPO market rebound358

Sources:

1. https://www.biospace.com/business/ipo-tracker-2026-eikon-clocks-largest-ipo-since-2024-generate-follows-as-ipo-tap-opens

2. https://www.fiercebiotech.com/biotech/agomab-spyglass-head-nasdaq-ipos-totalling-350m

3. https://www.statnews.com/2026/02/06/biotech-ipos-public-offerings-eikon/

5. https://european-biotechnology.com/latest-news/agomab-goes-public-on-nasdaq-as-biotech-ipos-top-1bn-in-a-single-week/

6. https://www.biopharmadive.com/news/eikon-biotech-ipo-price-cancer-drugs-2026/811169/

7. https://www.biopharmatrend.com/news/flagships-generate-biomedicines-eyes-ipo-amid-reopening-biotech-market-window-1491/

8. https://scrip.pharmaintelligence.informa.com/scrip/business/financing/finance-watch/finance-watch-four-ipos-in-one-week-3ZWVZV44XBHWVPEWW4OWN6O5WI/